
Henry Schein (HSIC) Stock Forecast & Price Target
Henry Schein (HSIC) Analyst Ratings
Bulls say
Henry Schein Inc demonstrated robust revenue growth across its key segments, with medical products revenue rising by 6.3% as reported, and the global technology segment revenues increasing by 7.4%. Additionally, the company's overall international business experienced a reported growth of 4.7%, indicating strong market performance. The expectation of mid-single-digit percentage growth in adjusted EBITDA further reinforces a positive financial outlook for the company.
Bears say
Henry Schein's recent financial performance has shown significant weaknesses, with a gross margin of 31.4% representing a decline of 110 basis points year-over-year, which also fell short of estimates by 60 basis points. The company's US dental merchandise revenue decreased by 1.2% due to pricing pressures, while international merchandise revenue, although reported up by 1.9%, faced a local internal decline of 0.4%. These factors contribute to a negative outlook for the company, highlighting issues with profitability and revenue growth in critical segments.
This aggregate rating is based on analysts' research of Henry Schein and is not a guaranteed prediction by Public.com or investment advice.
Henry Schein (HSIC) Analyst Forecast & Price Prediction
Start investing in Henry Schein (HSIC)
Order type
Buy in
Order amount
Est. shares
0 shares